

## EG 427 to hold poster presentation on lead asset EG110A at ESGCT

**Paris, France, October 10, 2023** – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions based on its unique non-replicative HSV-1 vector platform, announces today that it will hold a poster presentation outlining preclinical data on its lead asset EG110A at the European Society of Gene and Cell Therapy (ESGCT) 30<sup>th</sup> Annual Congress, taking place October 24-27 in Brussels, Belgium.

EG110A is an innovative non-replicative Herpes Simplex Virus 1 (nrHSV-1) vector, which has been designed to express a botulinum toxin fragment in bladder sensory neurons, whilst preserving motor neuron and muscle cell function. It has demonstrated proof-of-concept efficacy in relevant animal models for overactive bladder from neurologic origin (NDO) or not (OAB), and an Investigational New Drug (IND) data package is being prepared for submission.

nrHSV-1 vectors have unique characteristics which allow them to reach neuronal cells from their endings that are easily accessible with local injections. The first-in-class EG110A works by selectively silencing the sensory nerves of the bladder responsible for conveying pathogenic signal in these different indications, and has potential for long-term efficacy.

“We are looking forward to presenting our exciting product EG110A as a first example of our non-replicative HSV-1 vectors to the scientific community at the ESGCT 30<sup>th</sup> Annual Congress,” said Alberto Epstein, Ph.D., Founder and Chief Scientific Officer of EG 427. “The preclinical results so far are very promising, showing the potential of our vector construct to become the first gene therapy to treat bladder pathologies outside of oncology. Using a recombinant non-replicative HSV-1 vector is a unique approach to treat chronic neurologic diseases and opens up the possibility of also addressing other indications. We are looking forward to further investigating EG110A in the clinic, with an IND expected in Q1 2024.”


### Details of the oral presentation:

- **ESGCT 30<sup>th</sup> Annual Congress**, Brussels, Belgium, October 24-27, 2023
  - Julien Ratelade, Preclinical Project Manager, will present a poster on Wednesday, October 25 from 5:00-6:15pm CET and Thursday, October 26 from 8:30pm to 9:30pm CET.

### About EG 427

**EG 427** has developed a unique, non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform. It delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes. We take advantage of it to design new treatments of peripheral nervous system disorders and beyond. Our lead asset, EG110A, targets the silencing of type-C sensory neurons. It is first being developed in urology indications. Our earlier stage products are focused on modifying the neurotransmission of other subsets of neurons. Furthermore, we are building the necessary manufacturing efficiency to bring genomic medicine to more prevalent, high medical need indications.

For more information:



 check our website at [www.eq427.com](http://www.eq427.com)  
follows us on **LinkedIn** at [www.linkedin.com/company/eq427/](http://www.linkedin.com/company/eq427/)

**Contacts:**

**EG427**

Philippe Chambon, M.D., Ph.D.  
Founder and CEO  
[philippe@eg427.com](mailto:philippe@eg427.com)

**Investors**

Chris Maggos  
Cohesion Bureau  
[chris.maggos@cohesionbureau.com](mailto:chris.maggos@cohesionbureau.com)  
+41 79 367 62 54

**Media**

**US**

Selina Husain / Robert Flamm, Ph.D.  
Burns McClellan, Inc.  
[shusein@burnsmc.com](mailto:shusein@burnsmc.com)  
[rflamm@burnsmc.com](mailto:rflamm@burnsmc.com)

**EU**

Sophie Baumont  
Cohesion Bureau  
[sophie.baumont@cohesionbureau.com](mailto:sophie.baumont@cohesionbureau.com)  
+33 6 27 74 74 49